Safety and efficacy of azacitidine in myelodysplastic syndromes

被引：25
作者：
Vigil, Carlos E. [1 ]
Martin-Santos, Taida [1 ]
Garcia-Manero, Guillermo [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2010年 / 4卷
关键词：
Azacitidine; MDS; hypomethylating agents; MYELOID-LEUKEMIA; VALPROIC ACID; 5-AZACYTIDINE; TRANSPLANTATION; EXPRESSION; 5-AZA-2'-DEOXYCYTIDINE; METHYLATION; COMBINATION; ANTIGENS; CANCER;
D O I：
10.2147/DDDT.S3143
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Purpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. Summary: Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. Conclusion: Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.
引用
收藏
页码：221 / 229
页数：9
相关论文
共 54 条
[51]   Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome [J].
Soriano, Andres O. ;
Yang, Hui ;
Faderl, Stefan ;
Estrov, Zeev ;
Giles, Francis ;
Ravandi, Farhad ;
Cortes, Jorge ;
Wierda, William G. ;
Ouzounian, Souzanne ;
Quezada, Andres ;
Pierce, Sherry ;
Estey, Elihu H. ;
Issa, Jean-Pierre J. ;
Kantarjian, Hagop M. ;
Garcia-Manero, Guillermo .
BLOOD, 2007, 110 (07) :2302-2308
[52]   Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine [J].
Tang, Kai-Fu ;
He, Cai-Xia ;
Zeng, Gui-Li ;
Wu, Jinfeng ;
Song, Guan-Bin ;
Shi, Yi-Song ;
Zhang, Wei-guang ;
Huang, Ai-Long ;
Steinle, Alexander ;
Ren, Hong .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 370 (04) :578-583
[53]  
VOGLER WR, 1976, BLOOD, V48, P331
[54]   Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes [J].
Voso, Maria Teresa ;
Santini, Valeria ;
Finelli, Carlo ;
Musto, Pellegrino ;
Pogliani, Enrico ;
Angelucci, Emanuele ;
Fioritoni, Giuseppe ;
Alimena, Giuliana ;
Maurillo, Luca ;
Cortelezzi, Agostino ;
Buccisano, Francesco ;
Gobbi, Marco ;
Borin, Lorenza ;
Di Tucci, Anna ;
Zini, Gina ;
Petti, Maria Concetta ;
Martinelli, Giovanni ;
Fabiani, Emiliano ;
Fazi, Paola ;
Vignetti, Marco ;
Piciocchi, Alfonso ;
Liso, Vincenzo ;
Amadori, Sergio ;
Leone, Giuseppe .
CLINICAL CANCER RESEARCH, 2009, 15 (15) :5002-5007
123456